Related Experiment Video
Updated: Aug 18, 2025
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
12.3K
Heart Failure in Menopause: Treatment and New Approaches
Jaqueline S da Silva1,2, Tadeu Lima Montagnoli2, Mauro Paes Leme de Sá3
1Programa de Pós-Graduação em Cardiologia, Instituto do Coração Edson Saad, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
International Journal of Molecular Sciences
|December 11, 2022
Summary
Menopause exacerbates heart failure with preserved ejection fraction (HFpEF) in women by reducing estrogen
Area of Science:
- Cardiology and Women's Health
Background:
- Aging is a primary risk factor for heart failure (HF), with heart failure with preserved ejection fraction (HFpEF) disproportionately affecting elderly women.
- Sex differences in cardiovascular disease (CVD) are linked to decreased estrogen levels during menopause, impacting cardioprotective mechanisms.
- Estrogen receptors play a crucial role in modulating fibrotic, apoptotic, inflammatory, and calcium homeostasis processes vital for cardiac function.
Purpose of the Study:
- To explore the alterations in heart failure with preserved ejection fraction (HFpEF) associated with menopause.
- To identify potential therapeutic targets for mitigating HFpEF progression in postmenopausal women.
Main Methods:
- Review of preclinical menopause models and existing literature on HFpEF pathogenesis.
- Analysis of signaling pathways and organ systems implicated in menopause-induced HFpEF.
- Examination of the role of estrogen depletion in cardiovascular adaptation.
Main Results:
- Estrogen depletion during menopause diminishes cardioprotection, contributing to HFpEF development.
- Key pathways involved include renin-angiotensin system (RAS) dysregulation, chronic inflammation, and sympathetic nervous system alterations.
- Preclinical models highlight the complex interplay of signaling pathways and organ systems in HFpEF.
Conclusions:
- Menopause-induced estrogen deficiency is a significant factor in the development of HFpEF.
- Therapeutic strategies targeting estrogen-related pathways and associated systems (RAS, inflammation, sympathetic nervous system) show promise for treating HFpEF.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.6K
14:26A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
Published on: April 7, 2014
15.5K
Related Concept Videos
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
482
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
482
01:22Heart Failure VI: Adjunct Therapies
23
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
23
01:30Heart Failure VII: Nursing Interventions
130
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
130
01:29Cardiomyopathy V: Interprofessional Care
25
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
25
01:22Heart Failure Drugs: β-Blockers
412
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
412